Rhythm Pharmaceuticals Inc.

NASDAQ:RYTM  
8.85
-0.35 (-3.80%)
Products

Rhythm Pharmaceuticals Announces FDA Acceptance For Filing And Priority Review Of Supplemental New Drug Application For Imcivree®

Published: 11/15/2021 14:02 GMT
Rhythm Pharmaceuticals Inc. (RYTM) - Rhythm Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of Supplemental New Drug Application for Imcivree® (setmelanotide) for Patients With Bardet-biedl Syndrome and AlstrÖm Syndrome.
Rhythm Pharmaceuticals Inc - FDA Granted Priority Review of Snda and Assigned a Prescription Drug User Fee Act (pdufa) Goal Date of March 16, 2022.